Conducting gene function research? The worst scenario is "working for ages with the gene still expressing." An mRNA molecule may have a half-life of mere hours, while its protein counterpart can persist for days. Transient mRNA knockdown alone often fails to yield observable phenotypes. Now, we construct a "silencing ladder" from short-term suppression to permanent zero expression, comprehensively demystifying gene silencing technologies: siRNA, shRNA interference, CRISPRi, and CRISPR/Cas9 knockout.
siRNA — The "7-Day Quick Strike"
Mechanism
Gene silencing mediated by RNA interference (RNAi). Small interfering RNA (siRNA) serves as the RNAi trigger. siRNA binds proteins like Ago to form the RNA-induced silencing complex (RISC), guiding RISC to cleave and degrade target mRNA, thereby reducing expression of the gene of interest.
Figure 1. Diagram of the mechanism of action of siRNA
Product Features
Chemically synthesized double-stranded RNA (21-25 nt)
·Delivery format: Lyophilized siRNA powder
·Pros: Fast & simple (no vector construction); effects observable within 24h
·Cons: Limited to proliferating cells (ineffective in primary/non-dividing cells); high off-target risk
·Silencing efficiency: 30%-95% (delivery standard ≥70%)
·Applications: Rapid gene validation, regulatory pathway analysis, drug target screening
shRNA Lentivirus — The "Gold Standard" for Stable Silencing
Mechanism
RNAi-mediated silencing. Short hairpin RNA (shRNA) is processed by Dicer into siRNA, which loads into RISC to degrade target mRNA. Unlike transient siRNA, lentiviral-delivered shRNA integrates into the host genome, enabling sustained siRNA production and persistent silencing across cell divisions.
Figure 2. Diagram of the mechanism of action of shRNA
Product Features
·Delivery format: shRNA lentiviral particles / stable cell lines
·Pros: Genomic integration for long-term silencing; broad applicability (infects dividing/non-dividing cells)
·Cons: Longer timeline; requires BSL-2 lab; efficiency may decline after excessive passaging
·Silencing efficiency: 50%-90% (delivery standard ≥70%)
·Applications: Long-term functional studies, lethal gene analysis, target discovery
CRISPR/Cas9 Knockout — Permanent Zero Expression
Mechanism
Adapted from bacterial immunity. Cas9 nuclease complexed with sgRNA cleaves target DNA. Double-strand breaks are repaired via:
1.NHEJ: Error-prone repair introducing indels → frameshift mutations → gene knockout.
2.HDR (with donor template): Precise edits (e.g., mutations, insertions).
Figure 3. Diagram of the mechanism of action of CRISPR/Cas9
Product Features
·Delivery format: Plasmids / lentivirus / monoclonal cell lines
·Pros: Permanent inactivation; unambiguous phenotypes (100% efficiency in homozygotes)
·Cons: Requires off-target sequencing; unpredictable NHEJ edits may retain partial function
·Silencing efficiency: 100% (homozygous knockout)
·Applications: Permanent gene ablation, genetic stability studies, target discovery
CRISPRi — Reversible, Scarless, DNA-Uncut
Mechanism
Catalytically dead Cas9 (dCas9, e.g., D10A/H840A mutants) fused to repressors (e.g., KRAB) blocks transcription initiation without DNA cleavage. gRNA guides dCas9-repressor to promoter regions, physically obstructing RNA polymerase. Unlike RNAi (targets mRNA), CRISPRi acts at the DNA level and is reversible.
Figure 4. Diagram of the mechanism of action of CRISPRi
Product Features
·Delivery format: Plasmids / lentivirus / stable cell lines
·Pros: Reversible suppression; targets coding/non-coding RNAs; isoform-specific silencing
·Cons: Reduced efficacy for genes with hyperactive promoters
·Silencing efficiency: 70%-95%
·Applications: Lethal gene studies, transcript-specific regulation, target discovery
Technology Selection Guide
| Scenario | Recommended Tool |
Rapid validation (1-2 weeks) | siRNA |
| Long-term studies / hard-to-transfect cells | shRNA Lentivirus |
| Permanent gene inactivation | CRISPR/Cas9 Knockout |
Reversible silencing / specific isoform targeting | CRISPRi |
Sources
1.de Brito e Cunha D, Frederico A B T, Azamor T, et al. Biotechnological evolution of siRNA molecules: from bench tool to the refined drug[J]. Pharmaceuticals, 2022, 15(5): 575.
2.Karagiannis T C, El-Osta A. RNA interference and potential therapeutic applications of short interfering RNAs[J]. Cancer gene therapy, 2005, 12(10): 787-795
OBiO has been committed to providing integrated solutions for oncology research. We offer end-to-end technical services spanning gene screening, functional genomics studies, and mechanistic investigations — including plasmid construction, viral packaging, gene overexpression, gene silencing, stable cell line development, functional cellular assays, dual-luciferase reporter systems, and animal model establishment.
Request Now